Juvenile dermatomyositis is also a multisystemic autoimmune disease. Typical patients may have a typical rash of symmetrical telangiectasias, elevated serum myokinesis, myogenic electromyography damage and muscle biopsy changes. The typical juvenile dermatomyositis rash manifests as purplish red spots on the face up to the eyelids and diffuse purplish red dead spots centered on the periorbital area, and scaly erythema on the back of the hands, metacarpals, and extensor surfaces of the knuckles. The treatment and care of the acute phase of spotted juvenile dermatomyositis is important, especially when swallowing is difficult, avoid eating dry and hard food. Nasal feeding if necessary. In the remission period, massage or passive exercise should be performed as early as possible to prevent muscle atrophy and limb contracture, and gradually transition to active exercise. Medication includes adrenocorticosteroids, immunosuppressants (e.g. methotrexate, cyclosporine A, cyclophosphamide, azathioprine, hydroxychloroquine, immunoglobulins) Most children have an active disease period of 2 years. Complete remission can be achieved with treatment, but a few children may have multiple relapses or a chronic persistent state. The disease may persist for 3-5 years or longer.